Diadema Partners »

Black Diamond Therapeutics shares owned by Diadema Partners

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-12-31 $463k 190k 2.43

More positions owned by Diadema Partners

Viking Therapeutics (VKTX)
Vertex Pharmaceuticals Incorporated (VRTX)
Bridgebio Pharma (BBIO)
Spdr Series Trust State Street Spd Put Option (XBI)
Praxis Precision Medicines I Com New Put Option (PRAX)
Johnson & Johnson (JNJ)
Avidity Biosciences Ord Call Option (RNA)
Capricor Therapeutics Com New (CAPR)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Jazz Pharmaceuticals Shs Usd Call Option (JAZZ)
Terns Pharmaceuticals (TERN)
Apogee Therapeutics Call Option (APGE)
Structure Therapeutics Sponsored Ads Call Option (GPCR)
Regeneron Pharmaceuticals (REGN)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Diadema Partners

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
NEA Management Company
Vanguard Group
Acadian Asset Management
Marshall Wace
Siren
Arrowstreet Capital, Limited Partnership
Jane Street
Renaissance Technologies
BlackRock
Vestal Point Capital
Dimensional Fund Advisors
Millennium Management
Connor, Clark & Lunn Investment Management
AWM Investment Company

View all funds holding Black Diamond Therapeutics